Abstract
Acute myeloid leukemia (AML) is a markedly heterogeneous hematological malignancy that is most commonly seen in elderly adults. The response to current therapies to AML is quite variable, and very few new drugs have been recently approved for use in AML. This review aims to discuss the issues with current trial design for AML therapies, including trial end points, patient enrollment, cost of drug discovery and patient heterogeneity. We also discuss the future directions in AML therapeutics, including intensification of conventional therapy and new drug delivery mechanisms; targeted agents, including epigenetic therapies, cell cycle regulators, hypomethylating agents and chimeric antigen receptor T-cell therapy; and detail of the possible agents that may be incorporated into the treatment of AML in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 523-535 |
| Number of pages | 13 |
| Journal | Future Oncology |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| State | Published - Mar 2017 |
Bibliographical note
Publisher Copyright:© 2016 Future Medicine Ltd.
Funding
| Funders | Funder number |
|---|---|
| National Childhood Cancer Registry – National Cancer Institute | P30CA016672 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- AML
- clinical trials
- future direction
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Future prospects of therapeutic clinical trials in acute myeloid leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver